AFFECTION OF DIFFERENT ORGANS AND SYSTEMS IN HYPERURICEMIA AND GOUT
(LITERATURE REVIEW)
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i2.13128Keywords:
gout, hyperuricemia, comorbidity, cardiovascular risk factors, metabolic syndromeAbstract
SUMMARY. Gout is a chronic systemic metabolic disease, which is characterized by persistent hyperuricemia and an uprise of inflammatory reaction at the sites of sodium monourate crystals deposition. Gout plays the leading role among the reasons of inflammatory arthritis in men above 30 years old. Its part among rheumatic maladies in Ukraine is 1, 5–2 %. Gout is diagnosed in 1–3 % of adults worldwide, while hyperuricemia – in 4–20 %. Increased level of uric acid is one of the diagnostic criteria of metabolic syndrome, indication of high cardiovascular risk and is associated with endothelial dysfunction, oxidative stress, chronic inflammation and damage of other organs and systems.
The aim – to analyze up to date literature sources and draw the conclusions about increased uric acid levels in blood and its effects on various organs and systems in patients with asymptomatic hyperuricemia and gout.
Material and Methods. In the study there were used systematic and bibliometric analysis. Literature sources were concerning the circumstances of hyperuricemia uprise, its clinical and pathogenic features, and the impact on state of health in general; the role of these effects in the onset of gout, metabolic syndrome, cardiovascular complications and other.
Results. Prevalent literature sources with regard to asymptomatic hyperuricemia and gout were presented. The one and the other set a huge socioeconomic problem as they affect mainly men and women of working age. This leads to the significant restriction of professional activity, disability, and impairs the quality of life. Emphasis was set on hyperuricemia as one of the main risk factors of cardiovascular diseases, metabolic syndrome, kidney damage, mental disorders.
Conclusions. The conducted analysis of evidence-based literature proves that both – asymptomatic hyperuricemia and clinically manifested gout – remarkably aggravate the course of cardiovascular, endocrine, hepatobiliary, urinary and nervous systems diseases.
References
Kapustianska, A.A. (2013). Rannia diahnostyka podahrychnoho artrytu na etapi pervynnoi medyko-sanitarnoi dopomohy [Early diagnosis gouty arthritis during primary health care]. Svit medytsyny ta biolohii – World of Medicine and Biology, 4, 104-107 [in Ukrainian].
Singh, J.A. (2013) Racial and gender disparities among patients with gout. Curr. Rheumatol. Rep., 15(2), 307-321. DOI: 10.1007/s11926-012-0307-x.
Humphrey, Ch., Hulme, R., & Dalbeth, N. (2016). A qualitative study to explore health professionals’ experience of treating gout: understanding perceived barriers to effective gout management. Journal of Primary Health Care, 8, 149-156. DOI: 10.1071/hc15017.
Singh, J.A., & Strand, V. (2008). Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilization in US veterans. Ann. Rheum. Dis., 67(9), 1310-1316. DOI: 10.1136/ard.2007.081604.
Galozzi, P., Bindoli, S., & Doria, A. (2021) Autoinflammatory Features in Gouty Arthritis. J. Clin. Med., 10(9), 1880-1895. DOI: 10.3390/jcm10091880.
Bhole, V., de Vera, M., & Rahman, M. (2010) Epidemiology of gout in women: Fifty-two-year follow-up of a prospective cohort. Arthritis Rheum., 62(4), 1069-1076. DOI: 10.1002/art.27338.
Choi, H.K., & Curhan, G. (2005). Gout: epidemiology and lifestyle choices. Curr. Opin. Rheumatol., 17(3), 341-345.
Kuo, C.F., See, L.C., & Yu, K.H. (2013). Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford), 52(1), 127-134. DOI: 10.1093/rheumatology/kes223.
Fitzgerald, J.D., Dalbeth, N., & Mikuls, T. (2020). American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol., 72(6), 879-895. DOI: 10.1002/art.41247.
Kondratiuk, V.Ye, & Tarasenko, O.M. (2016). Hiperurykemiia ta podahra: suchasnyi stan problemy [Hyperuricemia and Gout: Modern State Problems]. Ukrainskyi revmatolohichnyi zhurnal – Ukrainian Journal of Rheumatology, 3(65), 30-36 [in Ukrainian].
Bilovola, O.M. (2018). Revmatolohiia. Kharkiv: Vyd-vo KhNMU [in Ukrainian].
Shuba, N.M., & Voronova, T.D. (2015). Podahra – multymorbydnaya patolohyya [Gout: Multimorbid Pathology]. Ukrainskyi revmatolohichnyi zhurnal – Ukrainian Journal of Rheumatology, 1 (59), 72-83 [in Russian].
Holovach, I.Yu., & Yehudina, Ye.D. (2019). Podahra: pohliad na vidomu khvorobu kriz pryzmu ostannikh vidkryttiv ta suchasnykh rekomendatsii [Gout: a look at a known disease through a prism of recent discoveries and modern recommendations]. Zdorovia Ukrainy – Health of Ukraine, 1, 14-16 [in Ukrainian].
Smiian, S.I. (2020). Patsiient iz podahroiu: vtracheni mozhlyvosti ta novi perspektyvy [Gout patient: lost opportunities and new perspectives]. Zdorovia Ukrainy – Health of Ukraine, 4(74), 54 [in Ukrainian].
Klauser, A.S., Halpern, E.J., Strobl, S., et al. (2019). Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. JAMA Cardiol., 4(10), 1019-1028. DOI: 10.1001/jamacardio.2019.3201.
(2016). Adaptovana klinichna nastanova «Profilaktyka sertsevo-sudynnykh zakhvoriuvan» [Adopted clinical guidelines “Prevention of cardiovascular diseases”] [in Ukrainian].
Khanna, D., Fitzgerald, J.D., & Khanna, P.P. (2012). American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacological and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken), 64(10), 1431-1446. DOI:10.1002/acr.21772.
Saag, K.G., & Choi, H. (2006). Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res. Ther., 8(1), 2. DOI: 10.1186/ar1907.
Culleton, B.F., Larson, M.G., Kannel, W.B., & Levy, D. (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med., 131(1), 7-13. DOI: 10.7326/0003-4819-131-1-199907060-00003.
Daniuk, I.O., Dotsenko, S.Ya., & Rekalov, D.H. (2018). Osoblyvosti remodeliuvannia livoho shlunochka u khvorykh arterialnoiu hipertenziieiu na foni pervynnoi podahry v zalezhnosti vid funktsionalnoho stanu nyrok [Features of Left Ventricle Remodeling in Patients with Hypertension on the Primary Gout Background depending on Gunctional State of Kidneys]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu – Ukrainian journal of Medicine, Biology and Sport, 3(12), 83-87 [in Ukrainian]. DOI: 10.26693/jmbs03.03.083.
Kuo, Ch.F., Yu, K.H., & Luo, Sh.F. (2010). Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumat., 49(6), 1189-1196. DOI: 10.1093/rheumatology/keq095.
Hladii, O.I., & Bodnar, Ya.Ya. (2015). Cvitlooptychnyi analiz endoteliotsytiv pry eksperymentalnii hiperurykemii [Analysis of Light Microscopy Findings of Endothelial Cells in Modelled Hyperuricemia]. Aktualni problemy suchasnoi medytsyny: Visnyk ukrainskoi medychnoi stomatolohichnoi akademii – Actual Problems of Modern Medicine. Bulletin of the Ukrainian Medical Stomatological Academy, 4(52), 212-215 [in Ukrainian].
Schillaci, G., Pasqualini, L., & Verdecchia, P. (2002). Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J. Am. Coll. Cardiol., 39(12), 2005-2011. DOI: 10.1016/s0735-1097(02)01896-x.
Krishnan, E., Pandya, B.J., & Chung, L. (2011). Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res. Ther., 13, 66-73. DOI: 10.1186/ar3322.
Mutluay, R., Deger, S.M., & Bahadir, E. (2012). Uric acid is an important predictor for hypertensive early atherosclerosis. Adv. Ther., 29(3), 276-286. DOI: 10.1007/s12325-012-0006-z.
Ndrepepa, G., Braun, S., & King, L. (2012). Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism, 61(12), 1780-1786. DOI: 10.1016/j.metabol.2012.05.014.
Alderman, M.H. (2001). Serum Uric Acid as a Cardiovascular Risk Factor for Heart Disease. Curr. Hypertens. Rep., 3(3), 184-189. DOI: 10.1007/s11906-001-0036-4.
Сhoi, K.H., & Curhan, G. (2007). Independent impact of gout on mortality and risk of coronary heart disease. Circulation, 116, 894-900. DOI: 10.1161/circulationaha.107. 703389.
Sánchez-Lozada, L.G., Tapia, E., & Avila-Casado, C. (2002). Mild hyperuricemia induces glomerular hypertension in normal rats. Am. J. Physiol. Renal. Physiol., 283(5), 1105-1110. DOI: 10.1152/ajprenal.00170.2002.
Feig, D.I., Madero, M., & Jalal, D.I. (2013). Uric acid and the origins of hypertension. J. Pediatr., 162(5), 896-902. DOI: 10.1016/j.jpeds.2012.12.078.
Lee, J.J., Ahn, J, & Hwang, J. (2015). Relationship between uric acid and blood pressure in different age groups. Clin. Hypertens., 21, 14-20. DOI: 10.1186/s40885-015-0022-9.
Franchuk, М. (2018). Podahrychna nefropatiia: otsinka vzaiemozviazkiv mizh perebihom podahry i rivnem mikroproteinurii [Gouty nephropathy: Evaluation of Association between Gout and Microproteinuria]. Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen – Journal of Clinical and Experimental Medical Research, 5, 939-944 [in Ukrainian].
Khyts, A.R. (2019). Podahra yak faktor ryzyku khvoroby nyrok [Gout as a Risk Factor for Kidney Disease]. Ukrainskyi medychnyi chasopys – Ukrainian Medical Journal, 10, 24 [in Ukrainian].
Stack, A.G., Johnson, M.E., & Blak, B. (2019). Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open, 9(8), 1-8. DOI: 10.1136/bmjopen-2019-031550.
Povorozniuk, V.V., & Dubetska, A.S. (2011). Hiperurykemiia ta podahra v liudei riznoho viku ta stati [Hyperuricemia and gout in Persons of all Ages and Genders]. Bil. Suhloby. Khrebet – Pain, Joints, Spine, 1(01), 73-79 [in Ukrainian].
Shen, C., Guo, Y., & Luo, W. (2013). Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can. J. Neurol. Sci., 40(1), 73-79. DOI: 10.1017/s0317167100012981.
Ruggiero, C., Cherubini, A., & Lauretani, F. (2009). Uric acid and dementia in community-dwelling older persons. Dement. Geriatr. Cogn. Disord., 27(4), 382-389. DOI: 10.1159/000210040.
Chamorro, Á., Amaro, S., & Castellanos, M. (2017). Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy. International Journal of Stroke, 12(4), 377-382. DOI: 10.1177/ 1747493016684354.
Kim, S.K. (2018). Interrelationship of Uric Acid, Gout, and Metabolic Syndrome: Focus on Hypertension, Cardiovascular Disease, and Insulin Resistance. J. Rheum. Dis., 25(1), 19-27. DOI: 10.4078/jrd.2018.25.1.19.
Thorp, A.A., & Schlaich, M.P. (2015). Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. J. Diabetes Res., 2015, 1-11. DOI: 10.1155/2015/341583.
Rahmouni, K., Correia, M.L., & Haynes, W.G. (2005). Obesity-associated hypertension: new insights into mechanisms. Hypertension, 45(1), 9-14. DOI: 10.1161/01.HYP.0000151325.83008.b4.
Mancia, G., De Backer, G., & Dominiczak, A. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH). J. Hypertens., 25(6), 1105-1187. DOI: 10.1097/hjh. 0b013e3281fc975a.
Stern, J.H., Rutkowski, J.M., & Scherer, P.E. (2016). Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab., 23(5), 770-784. DOI: 10.1016/j.cmet. 2016.04.011.
Khaniukov, O.O., Yehudina, Ye.D., & Kalashnykova, O.S. (2018). Arterialna hipertenziia u patsiientiv z hiperurykemiieiu: osnovy patohenezu, klinichne znachennia, diahnostyka, pidkhody do likuvannia [Arterial hypertension in patients with hyperuricemia: the basis of pathogenesis, clinical significance, diagnosis, approaches to treatment]. Arteryalnaia Hypertenzyia – Arterial Hypertension, 3(59), 37-49 [in Ukrainian].
Efstratiadis, G., Nikolaidou, C., & Vergoulas, G. (2007). Leptin as a cardiovascular risk factor. Hippokratia, 11(4), 163-170.
Zeng, R., Xu, C.H., & Xu, Y.N. (2014). Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq. Bras. Endocrinol. Metabol., 58(8), 817-823. DOI: 10.1590/0004-2730000003390.
Söderberg, S., Stegmayr, B., & Ahlbeck-Glader, C. (2003). High leptin levels are associated with stroke. Cerebrovasc. Dis., 15(1-2), 63-69. DOI: 10.1159/000067128.
Bhole, V., Choi, J.W., & Kim, S.W. (2010). Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am. J. Med., 123(10), 957-961. DOI: 10.1016/j.amjmed.2010.03.027.
Mount, D.B. (2013). The kidney in hyperuricemia and gout. Curr. Opin. Nephrol. Hypertens., 22(2), 216-223. DOI: 10.1097/mnh.0b013e32835ddad2.
Danchak, S.V. (2015). Dysmetabolichni porushennia u patsiientiv iz podahroiu v poiednanni z nealkoholnoiu zhyrovoiu khvoroboiu pechinky [Dysmethabolic disorders in patients with gout in combination with non-alcoholic fatty liver disease]. Visnyk naukovykh doslidzhen – Journal of Scientific Research, 3, 56-58 [in Ukrainian].
Skybchyk, V.A., & Voitovych, M.O. (2015). Nealkoholna zhyrova khvoroba pechinky: suchasna diahnostyka [Non-alcoholic fatty liver disease: modern diagnosis]. Hepatolohiia – Hepatology, 1, 52-56 [in Ukrainian].
Bodnar, P.M., Mykhalchyshyn, G.P., & Kobyliak, N.M. (2012). Nealkoholna zhyrova khvoroba pechinky u khvorykh na tsukrovyi diabet typu 2: patohenez, diahnostyka ta likuvannia (lektsiia) [Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: pathogenesis, diagnosis and treatment (lecture)]. Endokrynolohiia – Endocrinology, 17(1), 94-101 [in Ukrainian].
Arych, H.I. (2008). Kliniko – patohenetychni osoblyvosti perebihu podahry u khvorykh z urazhenniam hepatobiliarnoi systemy ta shliakhy yikh korektsii: avtoref. dys. na zdobuttia naukovoho stupenia kand.med.nauk: 14.01.02 – «Vnutrishni khvoroby» – Clinical and pathogenic features of gout in patients with hepatobiliary damage and ways of their correction: the thesis for the degree of Candidate of Medical Sciences : 14.01.02 – "Internal diseases", Kyiv: B. v. [in Ukrainian].
(2014). Adaptovana klinichna nastanova «Nealkoholna zhyrova khvoroba pechinky» [Adopted clinical guidelines “Non-alcoholic fatty liver disease”], Internal diseases, 14-18 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
